Arsenic Trioxide (ATO), a novel therapeutic agent for prostate and bladder cancers

Document Type: Review

Authors

1 Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

2 Isfahan University of Medical Sciences

10.22034/au.2020.223726.1011

Abstract

The effectiveness of the ATO in treating blood diseases is one of the most striking developments in modern medicine. In 1970, ATO as a toxin, it is also known as an ancient drug and was first used in combination with herbal extracts to treat ALP. One of the most important benefits of ATO is the failure of bone marrow suppression. ATO has been proposed as a novel and effective medicine for cancer prevention and treatment with various functions including, induction of apoptosis through re-activating the Wnt inhibitor, growth inhibition via activation of PI3K/AKT pathway, autophagy stimulation, induction of cell differentiation and angiogenesis via VEGFA-VEGFR2-PI3K/ERK signaling path in cancer cells and ATO may be involved in the acetylation of histones and interfering with gene transcription. ATO can increased synergistic effect in treatment and increased antitumor effects on prostate cancer cells via inhibiting Akt/mTOR signaling pathways,and so, ATO in combination with inhibiting glutathione synthesis can treat bladder cancer epithelial cells effectively.

Keywords